related documents
- A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. Conferences
- Body weight supported treadmill training in individuals with incomplete spinal cord injury: Effects on bone mass and body composition. Conferences
- Both oral and intravenous ibandronate effectively prevent postmenopausal bone loss in women without osteoporosis. Conferences
- Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis. Conferences
- Men present with a higher rate of prevalent fractures than women when started on bisphosphonate therapy in Canadian specialty osteoporosis practices. Conferences
- Participant characteristics that predict new clinically recognized vertebral fracture in postmenopausal women: The Canadian Multicentre Osteoporosis Study (CaMos). Conferences
- Predicting previous fracture with the health utilities index (HUI) mark II and III systems in both women and men: The Canadian Multicentre osteoporosis study (CaMos). Conferences
- Risk factors related with quality of life (QOL) in postmenopausal women with prevalent vertebral fractures: The Canadian Database of Osteoporosis and Osteopenia (CANDOO). Conferences
- Risk factors that predict new non-vertebral fracture in postmenopausal women: The Canadian Multicentre Osteoporosis Study (CaMos). Conferences
- The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women. Conferences
- The human cost of fractures in community dwelling older adults. Conferences
- The relations between lumbar spine, hip, distal femur and proximal tibia bone mineral density in healthy individuals. Conferences
- The relations between minimum joint space width in the knee and bone mineral density in the spine, hip, distal femur and proximal tibia. Conferences